CalciMedica, Inc. Announces 2025 Financial Results and Significant Clinical Updates

Key Highlights

• No Drug-Related Toxicity Identified in KOURAGE AKI Trial: Internal and external reviews of the unblinded Phase 2 KOURAGE trial data found no evidence of drug-related toxicity with Auxora™.
• Pivotal Program in Acute Pancreatitis (AP) Expected in 1H 2026: Design of the pivotal program for Auxora in AP to be finalized following positive FDA engagement.
• Promising Preclinical Data for CM5480 in Pulmonary Arterial Hypertension (PAH): JCI Insight publication demonstrates CM5480’s potential as a differentiated therapy. IND submission planned for 2027.
• Financial Position: \$13.0 million in cash and equivalents as of December 31, 2025; expected to fund operations into Q4 2026. Net loss widened to \$29.6 million.

Clinical and Corporate Developments

Acute Kidney Injury (AKI) Program Update

• Phase 2 KOURAGE Trial:
  • Trial evaluating Auxora in patients with Stage 2/3 AKI with acute hypoxemic respiratory failure (AHRF) was discontinued in January 2026 per Independent Data Monitoring Committee (IDMC) recommendation.
  • Reason: Safety concern due to a mortality imbalance. Review by IDMC and external experts found no evidence of drug-related toxicity; the imbalance likely stemmed from differences in patient disease severity at baseline.
  • CalciMedica intends to engage with the FDA in Q2 2026 to discuss the KOURAGE data and future AKI development strategy. Patient follow-up in KOURAGE continues.

Acute Pancreatitis (AP) Program Update

• Constructive FDA Engagement: CalciMedica is actively discussing the pivotal program design for Auxora in AP with the FDA, aiming to finalize in H1 2026. If successful, this would be the first U.S. pivotal program evaluating a therapy for AP, which causes about 300,000 hospitalizations annually in the U.S.
• Phase 2b CARPO Trial Published: Results from the randomized, dose-ranging study (214 patients) were published in eClinicalMedicine (Lancet Discovery Science). Key findings:
  • In hyper-inflamed patients, Auxora led to clinically meaningful, dose-dependent reductions in median time to solid food tolerance.
  • Across all patients, dose-dependent improvements observed in organ failure, necrotizing pancreatitis, and time to discharge.
  • Medium- and high-dose Auxora arms showed a statistically significant 100% reduction in new-onset severe respiratory failure vs. placebo.
  • High-dose Auxora achieved a statistically significant stratified win ratio of 1.640 (p < 0.05) on a composite endpoint (mortality, new-onset severe respiratory failure, necrotizing pancreatitis, and time to discharge).
  • Auxora was generally well-tolerated, with lower rates of serious adverse events at higher doses. No drug-related serious adverse events or deaths were seen at the high dose.

Pulmonary Arterial Hypertension (PAH) Program Update

• CM5480 Preclinical Success: Preclinical data published in JCI Insight (Nov 2025) show that CM5480, CalciMedica’s proprietary CRAC channel inhibitor, restores/improves heart function, gene expression, DNA repair, and metabolism in animal models of PAH. It significantly reduced right ventricular dysfunction both alone and with other PAH therapies.
• Ongoing IND-enabling Studies: Additional studies are underway to further characterize CM5480’s pharmacology, pharmacokinetics, and safety. IND filing targeted for 2027.

Financial Results (Year Ended December 31, 2025)

• Cash Position: \$13.0 million in cash, cash equivalents, and short-term investments, expected to fund operations into Q4 2026.
• R&D Expenses: \$15.2 million (up \$0.7 million from 2024) due to increased preclinical and clinical activities, partially offset by reduced manufacturing and personnel costs.
• G&A Expenses: \$7.9 million (down \$1.8 million from 2024) primarily due to lower consulting and professional service costs, partially offset by higher personnel (stock-based compensation).
• Other Expenses: \$6.4 million in other expenses vs. \$10.5 million in other income in 2024, driven by non-cash fair value adjustments, higher interest expense, and lower interest income.
• Net Loss: \$29.6 million (\$1.97 per share) vs. \$13.7 million (\$1.22 per share) in 2024, reflecting higher non-cash expenses and ongoing R&D investment.
• Balance Sheet: Total assets at \$13.6 million; total liabilities at \$20.2 million, including \$9.7 million promissory note and \$8 million warrant liability. Stockholders’ equity in deficit at -\$6.6 million.

Potential Share Price Movers & Shareholder Considerations

• Safety Data on Auxora: Confirmation of no drug-related toxicity in the KOURAGE trial could alleviate prior safety concerns and de-risk future development in AKI.
• Upcoming Regulatory Milestones: Finalization of the pivotal AP program design and FDA discussions on AKI will be key catalysts in 2026.
• Positive Clinical Efficacy Signals: Statistically significant results in the CARPO trial for AP and promising preclinical PAH data could increase investor confidence in Auxora and CM5480.
• Financial Runway: Sufficient cash to fund operations into Q4 2026, but negative equity and increased net loss highlight the need for future capital and careful monitoring of dilution risk.
• Pipeline Expansion: IND submission for CM5480 in PAH, if successful, would broaden CalciMedica’s pipeline into high-value indications.

Outlook

2026 will be a pivotal year for CalciMedica, with several regulatory and clinical milestones expected across its lead programs. Investors should monitor the outcomes of FDA interactions, the progression of pivotal trials in AP, and preclinical advances in PAH.

Contact

For further information, investors can contact Kevin Murphy at [email protected] or (212) 600-1902.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All information is derived from CalciMedica, Inc.’s official financial and clinical update for the year ended December 31, 2025. Forward-looking statements are subject to risks and uncertainties; actual results may differ materially. Investors should consult CalciMedica’s filings with the SEC and seek independent advice before making investment decisions.

View CalciMedica, Inc. Historical chart here